A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens

NCT07469488 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

122

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)
VTE (Venous Thromboembolism)
Rash Due to Epidermal Growth Factor Receptor Inhibitors
Infusion Reaction

Interventions

COMBINATION_PRODUCT: Enhanced dermatologic management
COMBINATION_PRODUCT: Enhanced IRR Prophylaxis
COMBINATION_PRODUCT: Enhanced VTE Prophylaxis (Cohort 1 only)

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China